STELLA PHARMA CORPORATION Logo

STELLA PHARMA CORPORATION

Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.

4888 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
大阪市中央区高麗橋三丁目2番7号 ORIX高麗橋ビル
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Stella Pharma Corporation is a pharmaceutical company engaged in the research, development, manufacturing, and sales of innovative drugs. The company specializes in Boron Neutron Capture Therapy (BNCT), a targeted radiation treatment for cancer. Its primary focus is on the development of boron compounds, including its approved drug Steboronine®, which is administered to patients prior to neutron irradiation. This therapy is primarily used for treating unresectable, locally advanced, or recurrent head and neck cancer. Stella Pharma aims to contribute to global healthcare by advancing BNCT as a new standard of care for various types of cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-26 07:06
Registration Form
確認書
Japanese 8.1 KB
2025-06-26 07:05
Annual Report
有価証券報告書-第18期(2024/04/01-2025/03/31)
Japanese 1.2 MB
2025-06-26 07:05
Governance Information
内部統制報告書-第18期(2024/04/01-2025/03/31)
Japanese 21.7 KB
2025-06-25 06:52
Post-Annual General Meeting Information
臨時報告書
Japanese 21.4 KB
2024-11-12 05:07
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-11-12 05:06
Interim Report
半期報告書-第18期(2024/04/01-2025/03/31)
Japanese 192.3 KB
2024-07-01 02:34
Post-Annual General Meeting Information
臨時報告書
Japanese 28.0 KB
2024-06-28 07:05
Governance Information
内部統制報告書-第17期(2023/04/01-2024/03/31)
Japanese 21.3 KB
2024-06-28 07:04
Registration Form
確認書
Japanese 8.1 KB
2024-06-28 07:04
Annual Report
有価証券報告書-第17期(2023/04/01-2024/03/31)
Japanese 1.1 MB
2024-02-14 05:13
Quarterly Report
四半期報告書-第17期第3四半期(2023/10/01-2023/12/31)
Japanese 145.0 KB
2024-02-14 05:13
Regulatory News Service
確認書
Japanese 8.1 KB
2023-11-14 06:08
Report Publication Announcement
確認書
Japanese 8.1 KB
2023-11-14 06:07
Quarterly Report
四半期報告書-第17期第2四半期(2023/07/01-2023/09/30)
Japanese 172.5 KB
2023-08-10 06:38
Report Publication Announcement
確認書
Japanese 8.1 KB

Automate Your Workflow. Get a real-time feed of all STELLA PHARMA CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for STELLA PHARMA CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
SK Bioscience Co.,Ltd Logo
A global biotech firm developing vaccines for diseases like COVID-19, influenza, and shingles.
South Korea 302440
SoftOx Solutions AS Logo
Develops non-toxic, AMR-safe antimicrobials for wound care, disinfection & airway infections.
Norway SOFTX
Solasia Pharma K.K. Logo
In-licenses and commercializes oncology treatments and supportive care products in Asia.
Japan 4597
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden SPAGO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden SPRINT
STADA Arzneimittel AG Logo
A leading European manufacturer of generics, consumer healthcare, and specialty pharmaceuticals.
Germany SAZ
Stayble Therapeutics AB Logo
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
Sweden STABL
STCUBE Logo
Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.
South Korea 052020

Talk to a Data Expert

Have a question? We'll get back to you promptly.